E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy
David Preiss,Sreenivasa Rao Kondapally,Paul Welsh,Sabina A. Murphy,Jennifer E. Ho,David D. Waters,David A. DeMicco,DPharm Philip Barter,Christopher P. Cannon,Marc S. Sabatine,Eugene Braunwald,John J.P. Kastelein,James A. de Lemos,Michael A. Blazing,Terje R. Pedersen,Matti J. Tikkanen,Naveed Sattar,Kausik K. Ray +17 more
TL;DR: In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dosestatin therapy.
Journal ArticleDOI
Studies on digitalis. i. direct effects on peripheral vascular resistance
Journal ArticleDOI
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction
TL;DR: This study evaluated the prognostic utility of several risk factors in the 3,339 patients enrolled in Phase II of the Thrombolysis in Myocardial Infarction (TIMI) trial and found that eight risk factors can be easily remembered and assessed in patients with myocardial infarction who are candidates for thrombectomy therapy and can be used to estimate short-term mortality.
Journal ArticleDOI
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
Samuel Z. Goldhaber,Michael F. Meyerovitz,Eugene Braunwald,David Green,Robert L. Vogelzang,Paul Citrin,John A. Heit,Michael Sobel,H. Brownell Wheeler,Dennis A. Plante,Hugh C. Kim,Alan Hopkins,Margaret Tufte,David C. Stump +13 more
TL;DR: In this paper, the authors compared the efficacy and safety of recombinant human tissue-type plasminogen activator (rt-PA, supplied as Activase®) with heparin alone or rt-PA plus heptonin in the treatment of proximal deep venous thrombosis (DVT) of the leg.
Journal ArticleDOI
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Kausik K. Ray,David A. Morrow,Marc S. Sabatine,Amy Shui,Nader Rifai,Christopher P. Cannon,Eugene Braunwald +6 more
TL;DR: Increased monocyte activation detected by an elevated plasma neopterin level identifies patients at long-term risk of death or recurrent acute coronary events after ACS and intensive statin therapy significantly attenuates the risk of recurrent events among patients with an elevated neopterIn level.